ArticleOpen forum infectious diseases2023
The Perils of Overly Sensitive Viral Load Testing for Persons With Human Immunodeficiency Virus.
Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Skills to Manage Pain Randomized Trial: Results of Antiretroviral Therapy Adherence, HIV Primary Care Retention, and Virologic Suppression Outcomes.Journal of acquired immune deficiency syndromes (1999) · 2025Trial
- Incidence and Risk Factors for Non-AIDS Comorbidities After COVID-19 in People Living With HIV in Atlanta, Georgia.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Determinants of Metabolic Syndrome in Virally Suppressed People Living with HIV: A Single-Center Comparative Analysis of Antiretroviral Regimens.Metabolites · 2026Article
- Suboptimal Patient-Provider Communication About Undetectable = Untransmittable and HIV Transmission Risk in Australia and the US.AIDS and behavior · 2025Article
- Higher levels of cell-associated HIV-1 RNA transcripts predict risk of viral blips: implications for clinical management and cure research.AIDS (London, England) · 2025Article
- Low HIV Viral Load Suppression and Its Implications for Controlling HIV among Refugee Adolescents and Youth Living in Refugee Settlements in Uganda: A Cross-sectional Analysis.AIDS and behavior · 2025Article
- Comparison of an In-House Multiplex Real-Time PCR Method With Altona Diagnostics Kits in the Detection of HSV, VZV, and EBV Viruses in Transplant Patients.BioMed research international · 2025Article
- Laboratory Report of HIV-1 Low-Level Viremia.Open forum infectious diseases · 2024Article
- MASLD in PLWH on ART: Predominance of Metabolic Risk Factors and Insights From Novel Biomarkers-A Cross-Sectional Study in Wrocław, Poland.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of "undetectable = untransmittable (U = U)" has been revolutionary in both the prevention and treatment of persons with human immunodeficiency virus (HIV). Most studies proving the concept of U = U used an HIV RNA (viral load [VL]) cutoff of 200 copies/mL to define being undetectable. Since then, increasingly sensitive commercial VL assays, sometimes down to a lower limit of detection (LLD) of 20 copies/mL, lead to confusion about the definition of "undetectable" and when someone is truly considered untransmittable. VLs between the LLD and 200 copies/mL have been associated with future virologic failure; however, no data exist to suggest that intervening in those patients leads to any meaningful benefits. In the absence of a demonstrable benefit of reporting such low VLs, we view this practice as harmful. We suggest recommendations for adjusting VL reporting and improving provider counseling, and call for research designs to mitigate the harms of overly sensitive VL testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.